Active peripheral inflammation is associated with pro-atherogenic lipid profile in psoriatic arthritis

Asha Shrestha, Asena Bahce-Altuntas, Wenzhu Bi Mowrey, Anna R. Broder

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Objective: The association between psoriatic arthritis (PsA) disease activity and lipid profiles has not been explored. We studied the association between active peripheral arthritis and/or enthesitis/daclylitis with lipid measurements in PsA. Methods: We conducted a cross-sectional study of PsA patients enrolled in the Consortium of Rheumatology Researchers of North American (CORRONA) registry. Low activity was defined as Clinical Disease Activity Index (CDAI) ≤ 10 without enthesitis or dactylitis. Moderate-to-high peripheral disease activity was defined as CDAI > 10 and/or the presence of enthesitis/dactylitis. Results: Of the 4672 patients with PsA enrolled in the CORRONA registry from June 2008 to October 2012, 725 (15.5%) had complete data on CDAI and lipid measurements. Of them, 284 (39%) patients had CDAI > 10 and/or enthesitis/dactylitis. Moderate-to-high group included more women and more current smokers. Patients with moderate-to-high disease activity had shorter duration of disease, and were more likely to be on prednisone, but less likely to use tumor necrosis factor (TNF) inhibitors. Moderate-to-high peripheral disease activity was associated with abnormal total cholesterol (TC) (>200. mg/dl), odds ratio (OR) = 1.58; 95% CI: (1.11, 2.24); . p = 0.01, and abnormal triglycerides (TG) (>150. mg/dl), OR = 1.64; 95% CI: (1.16, 2.32); . p = 0.005, after adjusting for gender, duration of PsA, smoking, body mass index, diabetes, modified Heath Assessment Questionnaire scores, as well as the following medications: methotrexate, other non-biologic disease modifying anti-rheumatic drugs, prednisone, TNF inhibitors, cholesterol lowering medications, and fish oil. The presence of enthesitis and/or dactylitis, irrespective of CDAI scores, was associated with abnormal TC, OR = 1.64; 95% CI: (1.08, 2.48); . p = 0.02. Conclusion: Our findings suggest an association between peripheral joint inflammation and lipid dysregulation in PsA. Further studies are needed to determine if treating PsA improves lipid profiles and cardiovascular mortality.

Original languageEnglish (US)
JournalSeminars in Arthritis and Rheumatism
DOIs
StateAccepted/In press - 2016

Fingerprint

Psoriatic Arthritis
Inflammation
Lipids
Odds Ratio
Rheumatology
Prednisone
Registries
Tumor Necrosis Factor-alpha
Cholesterol
Research Personnel
Anticholesteremic Agents
Antirheumatic Agents
Fish Oils
Methotrexate
Arthritis
Triglycerides
Body Mass Index
Cross-Sectional Studies
Joints
Smoking

Keywords

  • Cardiovascular risks
  • Disease activity
  • Lipids
  • Psoriatic arthritis

ASJC Scopus subject areas

  • Rheumatology
  • Anesthesiology and Pain Medicine

Cite this

@article{1877c41889cd46c8ada087f51e69573b,
title = "Active peripheral inflammation is associated with pro-atherogenic lipid profile in psoriatic arthritis",
abstract = "Objective: The association between psoriatic arthritis (PsA) disease activity and lipid profiles has not been explored. We studied the association between active peripheral arthritis and/or enthesitis/daclylitis with lipid measurements in PsA. Methods: We conducted a cross-sectional study of PsA patients enrolled in the Consortium of Rheumatology Researchers of North American (CORRONA) registry. Low activity was defined as Clinical Disease Activity Index (CDAI) ≤ 10 without enthesitis or dactylitis. Moderate-to-high peripheral disease activity was defined as CDAI > 10 and/or the presence of enthesitis/dactylitis. Results: Of the 4672 patients with PsA enrolled in the CORRONA registry from June 2008 to October 2012, 725 (15.5{\%}) had complete data on CDAI and lipid measurements. Of them, 284 (39{\%}) patients had CDAI > 10 and/or enthesitis/dactylitis. Moderate-to-high group included more women and more current smokers. Patients with moderate-to-high disease activity had shorter duration of disease, and were more likely to be on prednisone, but less likely to use tumor necrosis factor (TNF) inhibitors. Moderate-to-high peripheral disease activity was associated with abnormal total cholesterol (TC) (>200. mg/dl), odds ratio (OR) = 1.58; 95{\%} CI: (1.11, 2.24); . p = 0.01, and abnormal triglycerides (TG) (>150. mg/dl), OR = 1.64; 95{\%} CI: (1.16, 2.32); . p = 0.005, after adjusting for gender, duration of PsA, smoking, body mass index, diabetes, modified Heath Assessment Questionnaire scores, as well as the following medications: methotrexate, other non-biologic disease modifying anti-rheumatic drugs, prednisone, TNF inhibitors, cholesterol lowering medications, and fish oil. The presence of enthesitis and/or dactylitis, irrespective of CDAI scores, was associated with abnormal TC, OR = 1.64; 95{\%} CI: (1.08, 2.48); . p = 0.02. Conclusion: Our findings suggest an association between peripheral joint inflammation and lipid dysregulation in PsA. Further studies are needed to determine if treating PsA improves lipid profiles and cardiovascular mortality.",
keywords = "Cardiovascular risks, Disease activity, Lipids, Psoriatic arthritis",
author = "Asha Shrestha and Asena Bahce-Altuntas and Mowrey, {Wenzhu Bi} and Broder, {Anna R.}",
year = "2016",
doi = "10.1016/j.semarthrit.2016.05.011",
language = "English (US)",
journal = "Seminars in Arthritis and Rheumatism",
issn = "0049-0172",
publisher = "W.B. Saunders Ltd",

}

TY - JOUR

T1 - Active peripheral inflammation is associated with pro-atherogenic lipid profile in psoriatic arthritis

AU - Shrestha, Asha

AU - Bahce-Altuntas, Asena

AU - Mowrey, Wenzhu Bi

AU - Broder, Anna R.

PY - 2016

Y1 - 2016

N2 - Objective: The association between psoriatic arthritis (PsA) disease activity and lipid profiles has not been explored. We studied the association between active peripheral arthritis and/or enthesitis/daclylitis with lipid measurements in PsA. Methods: We conducted a cross-sectional study of PsA patients enrolled in the Consortium of Rheumatology Researchers of North American (CORRONA) registry. Low activity was defined as Clinical Disease Activity Index (CDAI) ≤ 10 without enthesitis or dactylitis. Moderate-to-high peripheral disease activity was defined as CDAI > 10 and/or the presence of enthesitis/dactylitis. Results: Of the 4672 patients with PsA enrolled in the CORRONA registry from June 2008 to October 2012, 725 (15.5%) had complete data on CDAI and lipid measurements. Of them, 284 (39%) patients had CDAI > 10 and/or enthesitis/dactylitis. Moderate-to-high group included more women and more current smokers. Patients with moderate-to-high disease activity had shorter duration of disease, and were more likely to be on prednisone, but less likely to use tumor necrosis factor (TNF) inhibitors. Moderate-to-high peripheral disease activity was associated with abnormal total cholesterol (TC) (>200. mg/dl), odds ratio (OR) = 1.58; 95% CI: (1.11, 2.24); . p = 0.01, and abnormal triglycerides (TG) (>150. mg/dl), OR = 1.64; 95% CI: (1.16, 2.32); . p = 0.005, after adjusting for gender, duration of PsA, smoking, body mass index, diabetes, modified Heath Assessment Questionnaire scores, as well as the following medications: methotrexate, other non-biologic disease modifying anti-rheumatic drugs, prednisone, TNF inhibitors, cholesterol lowering medications, and fish oil. The presence of enthesitis and/or dactylitis, irrespective of CDAI scores, was associated with abnormal TC, OR = 1.64; 95% CI: (1.08, 2.48); . p = 0.02. Conclusion: Our findings suggest an association between peripheral joint inflammation and lipid dysregulation in PsA. Further studies are needed to determine if treating PsA improves lipid profiles and cardiovascular mortality.

AB - Objective: The association between psoriatic arthritis (PsA) disease activity and lipid profiles has not been explored. We studied the association between active peripheral arthritis and/or enthesitis/daclylitis with lipid measurements in PsA. Methods: We conducted a cross-sectional study of PsA patients enrolled in the Consortium of Rheumatology Researchers of North American (CORRONA) registry. Low activity was defined as Clinical Disease Activity Index (CDAI) ≤ 10 without enthesitis or dactylitis. Moderate-to-high peripheral disease activity was defined as CDAI > 10 and/or the presence of enthesitis/dactylitis. Results: Of the 4672 patients with PsA enrolled in the CORRONA registry from June 2008 to October 2012, 725 (15.5%) had complete data on CDAI and lipid measurements. Of them, 284 (39%) patients had CDAI > 10 and/or enthesitis/dactylitis. Moderate-to-high group included more women and more current smokers. Patients with moderate-to-high disease activity had shorter duration of disease, and were more likely to be on prednisone, but less likely to use tumor necrosis factor (TNF) inhibitors. Moderate-to-high peripheral disease activity was associated with abnormal total cholesterol (TC) (>200. mg/dl), odds ratio (OR) = 1.58; 95% CI: (1.11, 2.24); . p = 0.01, and abnormal triglycerides (TG) (>150. mg/dl), OR = 1.64; 95% CI: (1.16, 2.32); . p = 0.005, after adjusting for gender, duration of PsA, smoking, body mass index, diabetes, modified Heath Assessment Questionnaire scores, as well as the following medications: methotrexate, other non-biologic disease modifying anti-rheumatic drugs, prednisone, TNF inhibitors, cholesterol lowering medications, and fish oil. The presence of enthesitis and/or dactylitis, irrespective of CDAI scores, was associated with abnormal TC, OR = 1.64; 95% CI: (1.08, 2.48); . p = 0.02. Conclusion: Our findings suggest an association between peripheral joint inflammation and lipid dysregulation in PsA. Further studies are needed to determine if treating PsA improves lipid profiles and cardiovascular mortality.

KW - Cardiovascular risks

KW - Disease activity

KW - Lipids

KW - Psoriatic arthritis

UR - http://www.scopus.com/inward/record.url?scp=84978517827&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84978517827&partnerID=8YFLogxK

U2 - 10.1016/j.semarthrit.2016.05.011

DO - 10.1016/j.semarthrit.2016.05.011

M3 - Article

JO - Seminars in Arthritis and Rheumatism

JF - Seminars in Arthritis and Rheumatism

SN - 0049-0172

ER -